Floatz logo

Atezolizumab

MSI-H Cancer

University Medical Center Groningenmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the MSI-H Cancer cohort.

Asset / SponsorPhaseRating
Tiragolumab
University Medical Center Groningen
Phase 2CCC
23me-00610
23andMe, Inc.
Phase 1/2CC
Ndi-219216
Nimbus Wadjet, Inc.
Phase 1/2CC
Decoy20
Indaptus Therapeutics, Inc
Phase 1/2CC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CC

View all 11 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →